ALPN-202 for Lymphoma (NEON-2 Trial)

"This clinical trial is accepting 29 adults aged 18-80 who have been diagnosed with lymphoma. The enrollees must also meet the following criteria: an ECOG performance status grade of 0-1, available tumor biopsy to represent their condition, life expectancy over 3 months and eligibility for treatment with a PD-1 or PD-L1 inhibitor, previous experience with at least 2 systemic anti-cancer therapies (lymphoma subjects only), recovery from non-laboratory toxicities resulting from prior anticancer therapy up to Grade ≤ 1 (with exceptions like alopecia and hearing loss) and adequate baseline function in terms of he"

"Participants in this medical trial must be between the ages of 18 and 80. However, there are 587 trials specifically for minors and 4705 clinical studies targeting those aged 65 or over."

"As this is a phase 1 trial, the safety of ALPN-202 has been approximated at 1 on the scale of 1 to 3 due to limited clinical data regarding its efficacy and security."

"ALPN-202 is commonly prescribed for the treatment of cancerous tumors, but can also be employed to combat unresectable melanoma and microsatellite instability high in addition to disease progression from chemotherapy."

"At the present moment, this research project is not seeking out any new participants. This clinical trial was originally published on June 22nd 2021 and had its most recent update on November 8th 2022. For those looking for other options, there are 4059 studies actively recruiting patients with lymphoma and 961 trials that require ALPN-202 participants."

"Currently, this medical trial is being conducted in 7 locations - with Boston, Cleveland and Grand Rapids among them. To limit travel needs while taking part in the study, it's important to select a site closest to you."

"This trial is no longer accepting participants; the original posting was made on June 22nd 2021, and it had its last amendment recorded on November 8th 2022. Alternative studies for lymphoma are abundant with 4059 clinical trials actively enrolling patients and 961 trials recruiting interested individuals to take part in ALPN-202 research."

"As of the present time, there are 961 ongoing studies for ALPN-202 with 122 trials in Phase 3. Houston, Texas is a primary hub for these clinical trials but they can also be found across 35731 unique locations worldwide."